By analyzing the potential mechanism of endogenous SMAC inefficiency, summarizing the latest preclinical and clinical outcomes of SMs in solid tumor treatment, and updating the cell death pathways regulated by SMs, we wish to deliver insight into the further application of SMs in cancer therapy. The gene discussed is DIABLO; the disease is cancer.